{"id":"rabeprazole-metronidazole-clarithromycin-amoxicillin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Metallic taste (metronidazole)"},{"rate":"3-8","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where the three antibiotics (metronidazole, clarithromycin, and amoxicillin) can effectively penetrate and kill H. pylori. Metronidazole and clarithromycin are bactericidal agents that disrupt bacterial protein synthesis and DNA, while amoxicillin inhibits bacterial cell wall synthesis. The combination approach reduces antibiotic resistance.","oneSentence":"This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:46.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":"Helicobacter Pylori Infection","enrollment":4447},{"nctId":"NCT03658746","phase":"PHASE4","title":"Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":420},{"nctId":"NCT03565484","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT01967329","phase":"PHASE4","title":"CANHelp Working Group Treatment Trials","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":338},{"nctId":"NCT04061447","phase":"NA","title":"Tailored Juice-guided Eradication Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2016-02-05","conditions":"Helicobacter Pylori Infection","enrollment":182},{"nctId":"NCT03997279","phase":"PHASE4","title":"Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii","status":"UNKNOWN","sponsor":"Clinical Centre of Serbia","startDate":"2019-06","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT03361267","phase":"NA","title":"Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection","status":"UNKNOWN","sponsor":"Inha University Hospital","startDate":"2017-12-30","conditions":"Helicobacter Pylori Infection, Compliance, Patient, Drug Resistance","enrollment":300},{"nctId":"NCT01264822","phase":"","title":"Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-01-13","conditions":"Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive","enrollment":108},{"nctId":"NCT02635191","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori in Children","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2014-03","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT01922765","phase":"PHASE4","title":"Concomitant Therapy of H. Pylori","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2013-08","conditions":"Gastritis, Gastric Ulcer, and Duodenal Ulcer","enrollment":540},{"nctId":"NCT01219764","phase":"PHASE4","title":"A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-10","conditions":"Helicobacter Infections","enrollment":200},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT01453036","phase":"PHASE4","title":"Clarithromycin Resistant Tailored Therapy","status":"COMPLETED","sponsor":"Jin Il Kim","startDate":"2011-08","conditions":"Peptic Ulcer, Helicobacter Pylori Infection","enrollment":924},{"nctId":"NCT01265069","phase":"PHASE4","title":"Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-11","conditions":"Helicobacter Pylori Infection","enrollment":204},{"nctId":"NCT01573975","phase":"PHASE4","title":"Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2009-01","conditions":"Helicobacter Pylori Infection","enrollment":345},{"nctId":"NCT01572597","phase":"PHASE4","title":"Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-06","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":120},{"nctId":"NCT01566643","phase":"PHASE4","title":"Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-01","conditions":"Helicobacter Pylori Infection","enrollment":231},{"nctId":"NCT00197418","phase":"PHASE2, PHASE3","title":"Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2003-08","conditions":"Helicobacter Infections, Gastritis, Gastric Ulcer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rabeprazole: Pariet","Metronidazole: Flagyl","Clarithromycin: Klacid","Amoxicillin: Amoxil"],"phase":"marketed","status":"active","brandName":"Rabeprazole, metronidazole, Clarithromycin, Amoxicillin","genericName":"Rabeprazole, metronidazole, Clarithromycin, Amoxicillin","companyName":"American University of Beirut Medical Center","companyId":"american-university-of-beirut-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}